33 results about "Subcutaneous implant" patented technology

Systems and methods involving implants positioned within implant pockets through minimally invasive entrance incisions, along with related neurostimulatory implants. In some implementations, implants may be folded, rolled, or otherwise compressed to fit within subcutaneous implant pockets, after which they may be decompressed to fit within an implant pocket having one or more dimensions substantially larger than the entrance incision. Such implants may be used for a variety of purposes, including generating electrical energy for various other implants, including neurostimulatory implants located throughout the body.

A method of pacing a heart includes implanting a subcutaneously implantable device on a xiphoid process and / or a sternum of a patient. The subcutaneously implantable device includes a housing, a prong extending away from the housing, and a first electrode at a distal end of the prong. The method further includes contacting a Manicka Zone of Pacing on an anterior surface of the heart with the first electrode on the distal end of the prong. The Manicka Zone of Pacing is defined as an area of the heart extending 3 centimeters (1.1811 inches) laterally outward from either side of a left anterior descending artery of the heart. A pacing signal is delivered to the Manicka Zone of Pacing of the heart through the first electrode. A right ventricle and a left ventricle of the heart are synchronously paced with the pacing signal received in the Manicka Zone of Pacing.

A subcutaneously implantable device a first housing, a clip attached to the first housing that is configured to anchor the device to a muscle, a bone, and / or a first tissue, and circuitry in the first housing that is configured to provide monitoring, therapeutic, and / or diagnostic capabilities with respect to an organ, a nerve, the first tissue, and / or a second tissue. The circuitry includes sensing circuitry and / or therapy circuitry, a first power source, and a transceiver. The device further includes an antenna attachment extending away from the first housing, wherein the antenna attachment is in electrical communication with the first power source and the transceiver, and wherein at least a portion of the antenna attachment is configured to be subcutaneously positioned in a patient.

Long-acting resorbable subcutaneous implant with extended release of pre-concentrated pharmacologically active substance in polymer for treatment of chronic adrenal insufficiency. The implant is inserted subcutaneously and has continuous release of the active ingredient for an extended period of time. The implant may have in its constitution only hydrocortisone but is preferably formed by hydrocortisone particles homogeneously dispersed in a bio erodible and bioabsorbable polymer matrix. Such a polymer matrix may be formed of a polymer or a polymer blend. The release of the drug in this system occurs through diffusion, at a relatively constant rate, and it is possible to change the rate of release of the drug through the thickness or material of this membrane.

An implantable medical device for use as an artificial urinary bladder can include a collection container configured to be placed in a patient's abdominal cavity and a pump configured to be subcutaneously placed outside the abdominal cavity to allow the patient to perceive the need for urination and controls timing of the urination. Flexible tubing can connect the patient's ureters to the collection container through anti-reflux valves preventing urine from flowing back to kidneys, connect the collection container to the pump through a unidirectional connection valve, and connect the pump to the patient's urethra through a unidirectional urethral valve to allow for urination through the patient's natural urethra.

A system for treating heart disease, such as pulmonary hypertension or right heart failure, including an implantable component and external components for monitoring the implantable component is provided. The implantable component may include a compliant member, e.g., balloon, coupled to a reservoir via a conduit. Preferably, the compliant member is adapted to be implanted in a pulmonary artery and the reservoir is adapted to be implanted subcutaneously. The external components may include a clinical controller component, monitoring software configured to run a clinician's computer, a patient monitoring device, and a mobile application configured to run on a patient's mobile device.

The present disclosure provides methods and a device for thyroxine delivery. This device is designed for subcutaneous implantation to ensure continuous delivery of thyroxine. It features a reservoir regulated by an embedded microprocessor with advanced signal software. The software triggers a precision pump to release a specific dose of thyroxine at regular intervals. This system enhances patient compliance and maintains optimal metabolic control.

A hair implant suitable for subcutaneous implantation is provided having an anchor comprising an anchor body, and at least one collagen receiving structure selected from the group consisting of at least one tunnel disposed through the anchor body or an external surface feature of the anchor body. The anchor further comprises at least one hair strand projecting from a distal end of the anchor body and alternatively wherein the at least one hair strand includes a bend, wherein the at least one collagen receiving structure, or the external surface feature, is configured to support collagen ligature growth after subcutaneous implantation of the hair implant so as to anchor the hair implant in the recipient. The hair implant includes a two-part construction having a base module formed of the anchor body and at least one hair stem configured for coupling with a long hair strand. Another hair implant alternative includes a hair strand having a first end that is passed through the skin, underneath and the up through the skin at another location to result in the hair strand having two portions projecting from the skin surface.

A composition and method for measuring the oxygen partial pressure of a tissue. The composition is implanted subcutaneously or into an organ inside a human body, and the oxygen partial pressure of the tissue is measured by fluorescence.

A subcutaneously implantable device includes a housing, a clip attached to the housing that is configured to anchor the device to a muscle, a bone, and / or a first tissue, and circuitry in the housing that is configured to provide monitoring, therapeutic, and / or diagnostic capabilities with respect to an organ, a nerve, the first tissue, and / or a second tissue. The circuitry includes sensing circuitry and / or therapy circuitry, a first power source, and a transceiver. The device further includes an antenna attachment including a head configured to be subcutaneously positioned in a patient and an arm extending between the housing and the head, wherein the head is in electrical communication with the first power source and the transceiver, and wherein the antenna attachment is flexible.

An example system includes an implantable medical device (IMD) that includes a housing configured for subcutaneous implantation proximate a lymphatic element of a patient; and a plurality of electrodes configured to sense an impedance signal indicative of one or more physiological parameters of the lymphatic element; and processing circuitry configured to: determine the one or more physiological parameters of the lymphatic element based on the impedance signal; determine a peripheral edema status of the patient based on the one or more physiological parameters; and output an indication of the peripheral edema status.

The invention discloses a testing method of a subcutaneous implantable drug delivery device, and relates to the technical field of medical testing. The method comprises the following steps that a to-be-tested subcutaneous implantable drug delivery device is placed in liquid simulating the subcutaneous environment, an infusion outlet of the to-be-tested subcutaneous implantable drug delivery device is connected with a back pressure simulation system, and the back pressure simulation system is used for forming controllable and dynamically-changeable back pressure at the infusion outlet. By introducing the controllable dynamic back pressure and the bionic liquid environment, the test condition for highly simulating the subcutaneous tissue is constructed, the defect of idealization of the test environment in the prior art is effectively overcome, and the obtained infusion performance data and the clinical actual performance have higher correlation degree. By monitoring the output quantity and the internal pressure in real time and combining with an intelligent fault diagnosis model, quantitative evaluation of the flow precision and stability of the device is realized, the device has fault early warning and life prediction capabilities, the test automation level is remarkably improved, and accurate data support is provided for product optimization and quality control.

This application discloses a safe subcutaneous implantation needle, which includes a soft tube, a connecting needle tube connected to the outlet end of the soft tube, a needle tip vertically connected to the outlet end of the connecting needle tube, a sleeve fixedly sleeved on the connecting needle tube, and a protective member connected to the top of the sleeve. The protective member can cover the needle tip. The protective member includes an open protective shell connected to the top of the sleeve, a vertical rod fixedly installed inside the top of the open protective shell, and a clamping plate obliquely fixedly installed at the bottom of the vertical rod. The needle tip can be clamped between the clamping plate and the vertical rod.

An apparatus (1, 50, 54) for subcutaneous implantation is disclosed. The apparatus (1, 50, 54) comprises a port (40) for receiving a percutaneous connector (55), the port (40) comprising an electrical contact (43) for providing electrical communication between the port (40) and the connector (55). Also disclosed is a percutaneous connector (55) for engaging a subcutaneously implanted port (40), an implantable control unit (1) for a medical device (60), a cardiac pump assembly (70) and an extracorporeal charging device (80).

A method of pacing a heart includes implanting a subcutaneously implantable device on a xiphoid process and / or a sternum of a patient. The subcutaneously implantable device includes a housing, a prong extending away from the housing, and a first electrode at a distal end of the prong. The method further includes contacting a Manicka Zone of Pacing on an anterior surface of the heart with the first electrode on the distal end of the prong. The Manicka Zone of Pacing is defined as an area of the heart extending 3 centimeters (1.1811 inches) laterally outward from either side of a left anterior descending artery of the heart. A pacing signal is delivered to the Manicka Zone of Pacing of the heart through the first electrode. A right ventricle and a left ventricle of the heart are synchronously paced with the pacing signal received in the Manicka Zone of Pacing.

Disclosed is a complex including: cellulose nanocrystals; at least one β-cyclodextrin molecule; and at least one curcumin molecule, suitable for use in the treatment of any kind of peripheral neuropathies. Further disclosed is a pharmaceutical composition including at least the complex and at least one pharmaceutically acceptable excipient. Also disclosed is the use of the complex or the pharmaceutical composition, in particular in the form of a hydrogel, a subcutaneous implant, an implantable pump, an implanted biofunctionalized nerve conduit, to improve the treatment compliance, to allow an extended release of the complex and to obtain better pharmacokinetics.

A method of pacing a heart includes implanting a subcutaneously implantable device on a xiphoid process and / or a sternum of a patient. The subcutaneously implantable device includes a housing, a prong extending away from the housing, and a first electrode at a distal end of the prong. The method further includes contacting a Manicka Zone of Pacing on an anterior surface of the heart with the first electrode on the distal end of the prong. The Manicka Zone of Pacing is defined as an area of the heart extending 3 centimeters (1.1811 inches) laterally outward from either side of a left anterior descending artery of the heart. A pacing signal is delivered to the Manicka Zone of Pacing of the heart through the first electrode. A right ventricle and a left ventricle of the heart are synchronously paced with the pacing signal received in the Manicka Zone of Pacing.

The invention discloses a subcutaneous implantable wireless energy supply device based on an organic photovoltaic technology and application of the subcutaneous implantable wireless energy supply device in subcutaneous implantable medical equipment. The subcutaneous implantation type wireless energy supply device based on the organic photovoltaic technology comprises a substrate, a first electrode, a hole transport layer, an active layer, an electron transport layer, a second electrode and a packaging layer which are arranged in sequence, wherein the substrate and the packaging layer are degradable flexible materials with biocompatibility; the active layer has the capability of absorbing light of 650 to 2500 nm; the second electrode is a transparent electrode. According to the invention, high performance, flexibility, biological safety and degradability are considered, the limitation of a traditional rigid photovoltaic device in implantation application is broken through, and an ideal self-energy-supply solution for next-generation implantable medical electronics is provided.

This invention discloses a permanent implantable arterial blood pressure monitoring system, comprising an in vivo implantation unit and an external monitoring unit. The in vivo implantation unit includes a pressure sensing head, a subcutaneous implantation module, and a hydraulic pressure transmission catheter. The pressure sensing head is implanted into the lumen of a target artery, and its outer surface is covered with an anticoagulant biological coating. The subcutaneous implantation module is implanted into the subcutaneous tissue adjacent to the target artery and includes a sealed shell, an energy conversion device, a miniature pressure sensor, a signal processing and transmission circuit, and a wireless transmission module. The hydraulic pressure transmission catheter is sealed at both ends to the pressure interfaces on the pressure sensing head and the subcutaneous implantation module shell, respectively. Its lumen is filled with incompressible fluid for transmitting blood pressure fluctuations to the miniature pressure sensor. This invention solves the problem that existing technologies cannot achieve continuous and accurate blood pressure monitoring while ensuring long-term safety by physically separating pressure sensing and signal conversion, thus combining accuracy and long-term implantation safety.

The invention discloses an epileptic seizure prediction system based on a subcutaneous implanted electrode and a processing method. Comprising a signal acquisition module, a preprocessing module, a feature extraction module, a prediction analysis module and an early warning module. The signal acquisition module is used for acquiring high-quality electroencephalogram signals through an electrode implanted under the skull skin; the preprocessing module carries out filtering and noise reduction on the signal; the feature extraction module extracts time domain and frequency domain low-level features through a first coding unit, and converts the time domain and frequency domain low-level features into high-level features for representation by using a pre-trained Transform encoder; the prediction analysis module calculates an epileptic seizure risk probability value based on the high-level features; and the early warning module triggers local early warning when the probability value exceeds a threshold. According to the invention, through combination of innovative hardware implantation and an advanced algorithm, high-precision, high-robustness and personalized adaptive epileptic seizure prediction is realized, and an effective early warning time window is provided for a patient.

The application discloses application of a traditional Chinese medicine composition in preparation of a medicine for treating iatrogenic abnormal uterine bleeding, and the traditional Chinese medicine composition is a gynecological Duanhong Yin capsule. After treatment of the gynecological Duanhong Yin capsule, abnormal uterine bleeding after use of a subcutaneous implant can be effectively improved, and the recurrence rate of patients is relatively low after three months of treatment, thus overcoming the problem that the recurrence rate is relatively high after treatment of existing medicines on abnormal uterine bleeding after use of a subcutaneous implant, and less patients have adverse reactions. In addition, the traditional Chinese medicine composition has short treatment time, fast effect, and can greatly improve the medical experience of patients. The application provides a new use of the traditional Chinese medicine composition in preparation of the medicine for treating the iatrogenic abnormal uterine bleeding, and provides a new treatment option for adverse reactions after use of a subcutaneous implant.

The utility model relates to the technical field of medical science, in particular to an implantable micropump dosing device which comprises a shell which is in a flat strip shape and internally provided with a liquid medicine storage container and a micropump for controlling liquid medicine release. An energy storage element for supplying energy to the micro pump is also arranged in the shell; the micropump is placed in the flat direction of the housing. The shell is in a flat strip shape and is made of a titanium material which is free of biotoxicity and stable in characteristic so as to adapt to an implantation position. The micro pump and the shell are arranged in parallel, so that the overall thickness of the drug delivery device is controlled within a small range, foreign body sensation after subcutaneous implantation is avoided, meanwhile, the inlet / outlet of the micro pump is in linear butt joint with the flow channel of the drug storage cavity, and fluid resistance is reduced.

Apparatus are disclosed that are arranged to be entirely subcutaneously-implanted, the apparatus comprising an electrochemical sensor for sensing at least one analyte, and a near-field communication (NFC) interface for percutaneous communication of information sensed by the electrochemical sensor.

A low-profile access port for subcutaneous implantation within a patient is disclosed. The access port includes a receiving cup that provides a relatively large subcutaneous target to enable catheter-bearing needle access to the port without difficulty. In one embodiment, a low-profile access port comprises a body including a conduit with an inlet port at a proximal end, and a receiving cup. The receiving cup is funnel shaped to direct a catheter-bearing needle into the conduit via the inlet port. The conduit is defined by the body and extends from the inlet port to an outlet defined by a stem. A bend in the conduit enables catheter advancement past the bend while preventing needle advancement. A valve / seal assembly is also disposed in the conduit and enables passage of the catheter therethrough while preventing fluid backflow. The body includes radiopaque indicia configured to enable identification of the access port via x-ray imaging.

A subcutaneously implantable device includes a housing, a clip attached to the housing that is configured to anchor the device to a muscle, a bone, and / or a first tissue, and circuitry in the housing that is configured to provide monitoring, therapeutic, and / or diagnostic capabilities with respect to an organ, a nerve, the first tissue, and / or a second tissue. The circuitry includes sensing circuitry and / or therapy circuitry, a first power source, and a transceiver. The device further includes an antenna attachment including a head configured to be subcutaneously positioned in a patient and an arm extending between the housing and the head, wherein the head is in electrical communication with the first power source and the transceiver, and wherein the antenna attachment is flexible.

1. Name of the designed product: transmitter. 2. Use of the designed product: for controlling and powering subcutaneously implanted electrodes. 3. Design points of the designed product: in shape. 4. Picture or photo best indicating the design points: assembly state diagram.

A subcutaneous implant removal device designed to work with a variety of cylindrical implants. The implant removal device comprises a non-planar base. The non-planar base is dimensioned to be placed onto the epidermal surface of a patient's skin. The base has a proximal end and a distal end. When placed on the patient's skin, the proximal end slopes upward while the distal end slopes downward along the patient's skin. The subcutaneous implant removal device also includes a pinnacle. The pinnacle extends upward from the non-planar base and has a front face and a rear face. The front face of the pinnacle is dimensioned to receive a force from a thumb of a clinician, holding the removal device in place on the patient's skin during use. A method for removing a subcutaneous implant is also provided.

Implantable access device for accessing the vascular system of a human or animal body, particularly subcutaneously implantable access port, comprising: a port body with at least one outlet opening connected or connectable to a catheter for accessing the vascular system of the human or animal body, a needle entrance with at least one inlet opening for receiving a needle, wherein the needle entrance is connected to the port body and movable relative to the port body between a first, unactuated operating condition and a second, actuated operating condition, and locking means for locking the needle entrance in the first, unactuated operating condition and in the second, actuated operating condition, wherein the locking means are activated by inserting the needle into the needle entrance and applying a predetermined movement to needle entrance via the inserted needle and / or by applying a predetermined movement to the needle entrance via the inserted needle and removing the needle from the needle entrance.

The present invention relates to a subcutaneous implant (2) comprising a housing (4) having at least a first zone (6) housing measuring instruments and / or communication equipment, a second zone (8) housing at least one printed circuit board, and a third zone (10) housing electrical energy storage means, wherein the printed circuit board comprises a plurality of electronic components including at least one accelerometer, and the printed circuit board is housed in a support configured to position the printed circuit board relative to at least the first zone (6) and / or the third zone (10) and to participate in the electrical insulation of at least some of the electronic components from the housing (4). (Figure 1)